Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

Edwin DeJesusOrlando Immunology CenterOrlando, Florida, USA

Jürgen K. RockstrohDepartment of MedicineUniversity of Bonn, Bonn, Germany

Jeffrey L. LennoxEmory University School of MedicineAtlanta, Georgia, USA

Michael S. SaagUniversity of Alabama at Birmingham, Birmingham, Alabama, USA

Adriano LazzarinUniversita Vita-Salute San RaffaeleMilan, Italy

Jing ZhaoMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Hong WanMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Anthony J. RodgersMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Monica L. WalkerMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Michael MillerMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Mark J. DiNubilePrincipal Investigators are listed in the Acknowledgments

Bach-Yen NguyenMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Hedy TepplerMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Randi LeavittMerck Sharp & DohmeWhitehouse Station, New Jersey, USA

Peter SklarMerck Sharp & DohmeWhitehouse Station, New Jersey, USACorrespondence[email protected]

& the STARTMRK Investigators show all

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

Information for

Open access

Opportunities

Help and information

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature